Management states Frances Creek valuation has increased to a little over 3 Billion. Financing required, will see which road they will take......Taken from their website with a release date of 31 July 2020: Business Strategy To Create Near Term Cash Flow Voyageur has created a very unique business model in the radio-contrast pharmaceutical market. A strategy to control all input costs from mineral production to pharmaceutical drug manufacturing. Our focus is on Barium & Iodine radio-contrast media drugs and carbon based drugs. Initially we will use strategic agreements that will result in immediate sales in India, followed by North America and then worldwide sales. Utilizing third party ingredients and manufacturing followed by Voyageur’ fully integrated manufacturing and production plants. Assets & Production Partners in Place to commence revenue generation Health Canada product registrations filed for barium radio-graphic contrast. All products are in final stage of review and will be granted. Strategic partnership established with ThinQ, securing iodine supply that will enable Voyageur to produce up to US$100,000,000 per year of revenue. Strategic Agreement with ThinQ News Link: https://voyageurpharmaceuticals.ca/voyageur-creates-strategic-agreement-with-thinq-for-future-drug-development/ Adding ThinQ to our team brings, scientific & drug formulation expertise and significant regulatory experience. FDA Applications for barium contrast to be filed upon closing of financing. The FDA is working diligently with Voyageur to ensure USA barium contrast monopoly is broken. USA distribution companies project $5million in sales of barium products immediately, with room to grow quickly into a USA $60,000,000 barium contrast market. A proven marketing strategy to leverage our barium contrast to acquire 20 times more sales of iodine contrast. For every bottle of barium sold, 20 bottles of iodine may be sold to the same customer. USA iodine market is $1,500,000,000 per year. ThinQ has granted Voyageur the right to use their iodine formulations for our generic Iopamidol and Iohexal product lines. India, USA and Canada regulatory submissions pending & will occur upon closing of financing. Voyageur and ThinQ are in negotiations with Indian contract manufacturing companies to begin immediate sales into the India market for iodine and barium contrast products. Upon conclusion of negotiations, Voyageur will begin sales within four-month period. Regulatory review in India can be expedited. Canada and USA to follow. Canada barium contrast manufacturing slated to begin upon approvals using third party ingredients and a third party drug manufacturing company located in Calgary. Diversifying our supply chain. Voyageur Frances Creek barium project has increased it value from CAD$5,000/tonne to $26,000/tonne as a result of full integration. FC resource established at 120,000 tonnes of barium sulfate which would equate to a 40 year supply. Use of Proceeds will fund PEA, Pre-feasibility reports and plant engineering all within six months of financing close. Upon completion a production pilot plant will be built and a bulk sample completed from the FC quarry (currently planned H1 2021). Pre-Feasibility report to be completed 3 months after PEA is issued, FC project will transition to reserve category and add substantial asset value to the company. Full quarry permit to be submitted after completion of bulk sample. Third party valuation discounted at 30% of $0.77 /share available upon request. Voyageur internal projections 5yrs: discount rate 15%, NPV before tax $280,200,000, IRR before tax 85.5%, cumulative net income over 5 years $800,900,000. Voyageur is implementing a strategy to begin cash flow using third party minerals and manufacturing. Upon completion of our full integration strategy, revenue and profits become robust with high growth rates over the long term, becoming the only fully integrated radio-contrast company globally. We expect early stage cash flow in early 2021.